Treating cancer with selective CDK4/6 inhibitors
- PMID: 27030077
- DOI: 10.1038/nrclinonc.2016.26
Treating cancer with selective CDK4/6 inhibitors
Abstract
Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at the heart of cancer as a pathological process. Clinical implementation of first-generation, nonselective CDK inhibitors, designed to inhibit this proliferation, was originally hampered by the high risk of toxicity and lack of efficacy noted with these agents. The emergence of a new generation of selective CDK4/6 inhibitors, including ribociclib, abemaciclib and palbociclib, has enabled tumour types in which CDK4/6 has a pivotal role in the G1-to-S-phase cell-cycle transition to be targeted with improved effectiveness, and fewer adverse effects. Results of pivotal phase III trials investigating palbociclib in patients with advanced-stage oestrogen receptor (ER)-positive breast cancer have demonstrated a substantial improvement in progression-free survival, with a well-tolerated toxicity profile. Mechanisms of acquired resistance to CDK4/6 inhibitors are beginning to emerge that, although unwelcome, might enable rational post-CDK4/6 inhibitor therapeutic strategies to be identified. Extending the use of CDK4/6 inhibitors beyond ER-positive breast cancer is challenging, and will likely require biomarkers that are predictive of a response, and the use of combination therapies in order to optimize CDK4/6 targeting.
Similar articles
-
Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.Am J Health Syst Pharm. 2019 Aug 1;76(16):1183-1202. doi: 10.1093/ajhp/zxz121. Am J Health Syst Pharm. 2019. PMID: 31369120 Review.
-
Recent advances of highly selective CDK4/6 inhibitors in breast cancer.J Hematol Oncol. 2017 Apr 24;10(1):97. doi: 10.1186/s13045-017-0467-2. J Hematol Oncol. 2017. PMID: 28438180 Free PMC article. Review.
-
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.Pharmacol Res. 2020 Jun;156:104686. doi: 10.1016/j.phrs.2020.104686. Epub 2020 Feb 14. Pharmacol Res. 2020. PMID: 32068118 Review.
-
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.Oncologist. 2017 Sep;22(9):1039-1048. doi: 10.1634/theoncologist.2017-0142. Epub 2017 Jul 13. Oncologist. 2017. PMID: 28706010 Free PMC article. Review.
-
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.Breast Cancer Res Treat. 2017 Nov;166(1):41-54. doi: 10.1007/s10549-017-4385-3. Epub 2017 Jul 24. Breast Cancer Res Treat. 2017. PMID: 28741274 Review.
Cited by
-
The current state of the art and future trends in RAS-targeted cancer therapies.Nat Rev Clin Oncol. 2022 Oct;19(10):637-655. doi: 10.1038/s41571-022-00671-9. Epub 2022 Aug 26. Nat Rev Clin Oncol. 2022. PMID: 36028717 Free PMC article. Review.
-
Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in Prostate Cancer.Adv Sci (Weinh). 2023 Dec;10(36):e2302368. doi: 10.1002/advs.202302368. Epub 2023 Nov 10. Adv Sci (Weinh). 2023. PMID: 37949681 Free PMC article.
-
Discovery of New Coumarin-Based Lead with Potential Anticancer, CDK4 Inhibition and Selective Radiotheranostic Effect: Synthesis, 2D & 3D QSAR, Molecular Dynamics, In Vitro Cytotoxicity, Radioiodination, and Biodistribution Studies.Molecules. 2021 Apr 14;26(8):2273. doi: 10.3390/molecules26082273. Molecules. 2021. PMID: 33919867 Free PMC article.
-
No QTc prolongation with CDK 4/6 inhibitor FCN-437c: results of a concentration-QTc analysis from a dedicated study in adult healthy subjects.Front Pharmacol. 2024 Aug 12;15:1433663. doi: 10.3389/fphar.2024.1433663. eCollection 2024. Front Pharmacol. 2024. PMID: 39188943 Free PMC article.
-
Managing therapeutic resistance in breast cancer: from the lncRNAs perspective.Theranostics. 2020 Aug 18;10(23):10360-10377. doi: 10.7150/thno.49922. eCollection 2020. Theranostics. 2020. PMID: 32929354 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical